+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Infectious Vaccines Market by Vaccine Type, Route of Administration, End User, Distribution Channel - Global Forecast 2026-2032- Product Image
Infectious Vaccines Market by Vaccine Type, Route of Administration, End User, Distribution Channel - Global Forecast 2026-2032- Product Image
Sale

Infectious Vaccines Market by Vaccine Type, Route of Administration, End User, Distribution Channel - Global Forecast 2026-2032

  • Report

  • 187 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 5674944
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Infectious Vaccines Market is projected to reach USD 38.23 Billion in 2026. It is expected to continue growing at a CAGR of 9.76%, reaching USD 66.98 Billion by 2032.

Infectious vaccines remain one of the highest-impact health technologies in global healthcare, preventing an estimated 3.5 million to 5 million deaths annually according to the World Health Organization. The infectious vaccines market is being shaped by sustained demand for pediatric immunization, adult booster programs, pandemic preparedness, travel vaccination, and protection against respiratory, vector-borne, and emerging infectious diseases.

Commercial momentum is supported by expanded use of mRNA, viral vector, recombinant protein, conjugate, live-attenuated, inactivated, and adjuvanted vaccine platforms. At the same time, public-sector procurement, Gavi-supported programs, national immunization schedules, and regulatory harmonization continue to influence access, pricing, and launch sequencing across developed and emerging markets.

Transformative Shifts in the Infectious Vaccines Landscape

The infectious vaccines landscape is shifting from episodic disease control toward continuous immunization readiness. COVID-19 accelerated regulatory collaboration, real-world safety monitoring, cold-chain investment, genomic surveillance, and platform-based vaccine development, creating faster pathways for vaccines targeting influenza, RSV, pneumococcal disease, HPV, malaria, dengue, tuberculosis, and future zoonotic threats.

Manufacturers are also adapting to combination vaccines, thermostable formulations, needle-free delivery research, and localized production. Demand is increasingly influenced by vaccine confidence, supply resilience, equitable access, antimicrobial resistance prevention, and the ability to demonstrate real-world effectiveness across infants, adolescents, adults, older adults, pregnant populations, travelers, and immunocompromised groups.

Cumulative Impact of Artificial Intelligence on Vaccine Innovation

Artificial intelligence is increasingly used across vaccine discovery, antigen selection, epitope mapping, immunogenicity prediction, clinical trial optimization, pharmacovigilance, and manufacturing analytics. AI-enabled models can accelerate candidate screening and support strain surveillance for pathogens with high mutation rates, including influenza, SARS-CoV-2, and other respiratory viruses.

The cumulative impact of AI is most visible when combined with high-quality genomic surveillance, electronic health records, immunization registries, and post-market safety databases. However, industry leaders must manage data bias, explainability, cybersecurity, validation standards, and regulatory acceptance to ensure AI improves vaccine speed without compromising safety, equity, or scientific rigor.

Key Regional Insights Across Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific is a high-priority region due to large birth cohorts, expanding domestic vaccine manufacturing, and rising government immunization investment, with China, India, Japan, South Korea, and Australia playing distinct roles in supply, R&D, regulatory strengthening, and advanced clinical adoption. North America remains a leading innovation and commercialization hub, supported by mature regulatory systems, adult immunization programs, strong biomedical research funding, and established CDC and Health Canada vaccination guidance.

Latin America continues to prioritize public procurement and regional disease control, with Brazil and Mexico central to demand for pediatric, HPV, influenza, pneumococcal, and outbreak-response vaccines. Europe benefits from centralized regulatory expertise, national immunization technical advisory groups, disease surveillance networks, and strong uptake of combination, travel, RSV, influenza, and HPV vaccines, while the Middle East is increasing investment in health security, preventive care, local manufacturing, and cold-chain infrastructure. Africa represents a critical access and impact region, where Gavi, UNICEF, WHO, Africa CDC, and national ministries support immunization against measles, polio, pneumococcal disease, rotavirus, HPV, malaria, yellow fever, cholera, and other high-burden infections.

Key Group Insights for ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN markets are strengthening immunization coverage through public-sector programs, regional manufacturing partnerships, and expanded surveillance for dengue, influenza, measles, and respiratory pathogens. The GCC is investing in preventive healthcare, life sciences localization, medical countermeasure readiness, and pandemic preparedness, making infectious vaccines a strategic pillar of national health security.

The European Union provides regulatory scale through the European Medicines Agency and coordinated public health initiatives, while BRICS countries combine large population demand with growing vaccine production capacity, public procurement influence, and expanding disease surveillance systems. G7 nations remain central to vaccine R&D financing, advanced manufacturing, and global health funding, and NATO members increasingly frame vaccine resilience, stockpiling, continuity of supply, and medical countermeasures as part of biosecurity and civil preparedness.

Key Country Insights Across Major Infectious Vaccine Markets

The United States leads in vaccine biotechnology, federal procurement capacity, real-world evidence infrastructure, and adult immunization commercialization, while Canada emphasizes public health guidance, influenza prevention, equity-focused access, and provincial immunization delivery. Mexico and Brazil are important Latin American markets, with Brazil’s public immunization infrastructure and local production capabilities supporting large-scale uptake, and Mexico maintaining demand through pediatric, influenza, HPV, and outbreak-prevention programs. In Europe, the United Kingdom, Germany, France, Italy, and Spain sustain demand through national immunization programs, aging populations, travel medicine, and adoption of RSV, pneumococcal, influenza, HPV, and combination vaccines; Russia maintains domestic vaccine capabilities and public-sector immunization priorities.

China and India are pivotal due to population scale, domestic production, regulatory modernization, and expanding innovation pipelines, with India also serving as a major global vaccine supplier for routine immunization programs. Japan prioritizes high-quality regulatory review, post-marketing safety, and aging-population vaccination, Australia maintains strong immunization registries and public health surveillance, and South Korea is advancing biomanufacturing, CDMO capacity, clinical research, and infectious disease preparedness.

Actionable Recommendations for Infectious Vaccine Industry Leaders

Industry leaders should prioritize diversified antigen portfolios, resilient supply chains, and platform technologies that can be rapidly adapted to outbreak, seasonal, and endemic disease needs. Organizations should align launch strategies with national immunization schedules, payer evidence requirements, real-world effectiveness data, and population-specific burden-of-disease analysis.

Executives should also invest in regional manufacturing partnerships, cold-chain optimization, pharmacovigilance automation, genomic surveillance integration, and vaccine confidence programs. Strategic differentiation will come from combination products, improved durability, simplified administration, thermostability, and robust evidence demonstrating reductions in hospitalizations, antimicrobial use, mortality, transmission, and overall healthcare costs.

Research Methodology for Infectious Vaccines Market Analysis

This executive summary is developed through secondary research using publicly available and verifiable sources, including WHO, CDC, UNICEF, Gavi, national immunization technical advisory groups, regulatory agencies, peer-reviewed literature, public health surveillance systems, and recognized global health databases. The analysis prioritizes evidence related to vaccine coverage, disease burden, platform innovation, procurement systems, safety monitoring, and regional health policy.

Insights are synthesized through data triangulation, trend mapping, technology assessment, and policy review. Qualitative interpretation is applied to compare regional demand drivers, manufacturing capabilities, regulatory dynamics, access barriers, immunization infrastructure, and competitive positioning within the infectious vaccines ecosystem, without relying on market sizing, share estimates, or forecasts.

Conclusion: Strategic Outlook for Infectious Vaccines

The infectious vaccines market is entering a more strategic phase defined by platform agility, AI-enabled discovery, public-private preparedness, genomic surveillance, and broader adult immunization. Long-term value will depend on reliable supply, regulatory trust, real-world evidence, vaccine confidence, and the ability to address both high-income booster markets and under-immunized populations.

Organizations that combine scientific innovation with equitable access, manufacturing resilience, transparent safety monitoring, and data-driven commercialization will be best positioned to capture growth opportunities while strengthening global protection against preventable infectious diseases.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Infectious Vaccines Market, by Vaccine Type
7.1. Conjugate
7.1.1. Hib Conjugate
7.1.2. Meningococcal Conjugate
7.1.3. Pneumococcal Conjugate
7.2. Inactivated
7.2.1. Hepatitis A
7.2.2. Influenza
7.2.3. Polio
7.2.4. Rabies
7.3. Live Attenuated
7.3.1. Influenza Laiv
7.3.2. Measles
7.3.3. Oral Polio
7.3.4. Rubella
7.3.5. Varicella
7.4. MRNA
7.4.1. Lipid Nanoparticle MRNA
7.4.2. Self-Amplifying MRNA
7.5. Subunit
7.5.1. Protein Subunit
7.5.2. Virus-Like Particle
7.6. Toxoid
7.6.1. Diphtheria
7.6.2. Pertussis
7.6.3. Tetanus
7.7. Viral Vector
7.7.1. Adenovirus
7.7.2. MVA
7.7.3. VSV
8. Infectious Vaccines Market, by Route Of Administration
8.1. Intradermal
8.2. Intramuscular
8.3. Intranasal
8.4. Oral
8.5. Subcutaneous
9. Infectious Vaccines Market, by End User
9.1. Clinics
9.1.1. General Practice
9.1.2. Specialty
9.2. Hospitals
9.2.1. Private
9.2.2. Public
9.3. Pharmacies
9.3.1. Online
9.3.2. Retail
9.4. Public Health Centers
9.4.1. Rural
9.4.2. Urban
10. Infectious Vaccines Market, by Distribution Channel
10.1. Government Agencies
10.1.1. Local
10.1.2. National
10.2. Hospital Pharmacies
10.2.1. In-Hospital
10.2.2. Outpatient
10.3. Online Pharmacies
10.3.1. Direct
10.3.2. Platform
10.4. Retail Pharmacies
10.4.1. Chain
10.4.2. Independent
11. Asia-Pacific Infectious Vaccines Market
12. North America Infectious Vaccines Market
13. Latin America Infectious Vaccines Market
14. Europe Infectious Vaccines Market
15. Middle East Infectious Vaccines Market
16. Africa Infectious Vaccines Market
17. ASEAN Infectious Vaccines Market
18. GCC Infectious Vaccines Market
19. European Union Infectious Vaccines Market
20. BRICS Infectious Vaccines Market
21. G7 Infectious Vaccines Market
22. NATO Infectious Vaccines Market
23. United States Infectious Vaccines Market
24. Canada Infectious Vaccines Market
25. Mexico Infectious Vaccines Market
26. Brazil Infectious Vaccines Market
27. United Kingdom Infectious Vaccines Market
28. Germany Infectious Vaccines Market
29. France Infectious Vaccines Market
30. Russia Infectious Vaccines Market
31. Italy Infectious Vaccines Market
32. Spain Infectious Vaccines Market
33. China Infectious Vaccines Market
34. India Infectious Vaccines Market
35. Japan Infectious Vaccines Market
36. Australia Infectious Vaccines Market
37. South Korea Infectious Vaccines Market
38. Competitive Landscape
38.1. Market Concentration Analysis, 2025
38.1.1. Concentration Ratio (CR)
38.1.2. Herfindahl Hirschman Index (HHI)
38.2. Recent Developments & Impact Analysis, 2025
38.3. Product Portfolio Analysis, 2025
38.4. Benchmarking Analysis, 2025
39. Company Profiles
39.1. Adimmune Corporation
39.2. AstraZeneca plc
39.3. Bavarian Nordic
39.4. Bharat Biotech
39.5. Biological E Limited
39.6. BioNTech SE
39.7. CanSino Biologics
39.8. China National Biotechnology Group
39.9. CSL Limited
39.10. Dynavax Technologies
39.11. Emergent BioSolutions, Inc.
39.12. GlaxoSmithKline plc
39.13. Haffkine Bio-Pharmaceutical Corporation
39.14. Inovio Pharmaceuticals
39.15. Johnson & Johnson
39.16. Merck & Co., Inc.
39.17. Mitsubishi Tanabe Pharma
39.18. Moderna, Inc.
39.19. Novavax, Inc.
39.20. Pfizer Inc.
39.21. Sanofi S.A.
39.22. Serum Institute of India
39.23. Sinovac Biotech Ltd.
39.24. Valneva SE
39.25. VBI Vaccines, Inc.
List of Figures
FIGURE 1. GLOBAL INFECTIOUS VACCINES MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL INFECTIOUS VACCINES MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL INFECTIOUS VACCINES MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL INFECTIOUS VACCINES MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL INFECTIOUS VACCINES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL INFECTIOUS VACCINES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 19. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 21. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 23. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 25. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 35. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. GCC INFECTIOUS VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 37. GCC INFECTIOUS VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. BRICS INFECTIOUS VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. BRICS INFECTIOUS VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. G7 INFECTIOUS VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. G7 INFECTIOUS VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. NATO INFECTIOUS VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. NATO INFECTIOUS VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 47. CANADA INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 48. MEXICO INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 49. BRAZIL INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 50. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. GERMANY INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. FRANCE INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. RUSSIA INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. ITALY INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. SPAIN INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. CHINA INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. INDIA INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. JAPAN INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. AUSTRALIA INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. SOUTH KOREA INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL INFECTIOUS VACCINES MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL INFECTIOUS VACCINES MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL INFECTIOUS VACCINES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CONJUGATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CONJUGATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL HIB CONJUGATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL HIB CONJUGATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL HIB CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL MENINGOCOCCAL CONJUGATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL MENINGOCOCCAL CONJUGATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL MENINGOCOCCAL CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL PNEUMOCOCCAL CONJUGATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL PNEUMOCOCCAL CONJUGATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL PNEUMOCOCCAL CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL INACTIVATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL INACTIVATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL INACTIVATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL HEPATITIS A MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL HEPATITIS A MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL HEPATITIS A MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL INFLUENZA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL INFLUENZA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL INFLUENZA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL POLIO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL POLIO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL POLIO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL RABIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL RABIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL RABIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL LIVE ATTENUATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL LIVE ATTENUATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL LIVE ATTENUATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL INFLUENZA LAIV MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL INFLUENZA LAIV MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL INFLUENZA LAIV MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL MEASLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL MEASLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL MEASLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ORAL POLIO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ORAL POLIO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ORAL POLIO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL RUBELLA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL RUBELLA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL RUBELLA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL VARICELLA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL VARICELLA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL VARICELLA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL MRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL MRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL MRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL LIPID NANOPARTICLE MRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL LIPID NANOPARTICLE MRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL LIPID NANOPARTICLE MRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL SELF-AMPLIFYING MRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL SELF-AMPLIFYING MRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL SELF-AMPLIFYING MRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL SUBUNIT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL SUBUNIT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL SUBUNIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL PROTEIN SUBUNIT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL PROTEIN SUBUNIT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL PROTEIN SUBUNIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL VIRUS-LIKE PARTICLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL VIRUS-LIKE PARTICLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL VIRUS-LIKE PARTICLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL TOXOID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL TOXOID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL TOXOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL DIPHTHERIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL DIPHTHERIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL DIPHTHERIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL PERTUSSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL PERTUSSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL PERTUSSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL TETANUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL TETANUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL TETANUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL VIRAL VECTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL VIRAL VECTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL VIRAL VECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL ADENOVIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL ADENOVIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL ADENOVIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL MVA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL MVA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL MVA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL VSV MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL VSV MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL VSV MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL INTRADERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL INTRADERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL INTRADERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL INTRANASAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL INTRANASAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL INTRANASAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL GENERAL PRACTICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL GENERAL PRACTICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL GENERAL PRACTICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL SPECIALTY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL SPECIALTY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL SPECIALTY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL PRIVATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL PRIVATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL PRIVATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL PUBLIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL PUBLIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL PUBLIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL RETAIL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL RETAIL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL RETAIL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL PUBLIC HEALTH CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL PUBLIC HEALTH CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 142. GLOBAL PUBLIC HEALTH CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL RURAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 144. GLOBAL RURAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 145. GLOBAL RURAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL URBAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 147. GLOBAL URBAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 148. GLOBAL URBAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 149. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 150. GLOBAL GOVERNMENT AGENCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 151. GLOBAL GOVERNMENT AGENCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 152. GLOBAL GOVERNMENT AGENCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 153. GLOBAL LOCAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 154. GLOBAL LOCAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 155. GLOBAL LOCAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 156. GLOBAL NATIONAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 157. GLOBAL NATIONAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 158. GLOBAL NATIONAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 159. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 160. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 161. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 162. GLOBAL IN-HOSPITAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 163. GLOBAL IN-HOSPITAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 164. GLOBAL IN-HOSPITAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 165. GLOBAL OUTPATIENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 166. GLOBAL OUTPATIENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 167. GLOBAL OUTPATIENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 168. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 169. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 170. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 171. GLOBAL DIRECT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 172. GLOBAL DIRECT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 173. GLOBAL DIRECT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 174. GLOBAL PLATFORM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 175. GLOBAL PLATFORM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 176. GLOBAL PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 177. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 178. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 179. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 180. GLOBAL CHAIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 181. GLOBAL CHAIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 182. GLOBAL CHAIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 183. GLOBAL INDEPENDENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 184. GLOBAL INDEPENDENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 185. GLOBAL INDEPENDENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 186. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 187. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 188. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
TABLE 189. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
TABLE 190. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
TABLE 191. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
TABLE 192. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
TABLE 193. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
TABLE 194. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 195. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 196. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 197. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 198. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 199. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
TABLE 200. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
TABLE 201. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 202. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
TABLE 203. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 204. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 205. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 206. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 207. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 208. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
TABLE 209. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
TABLE 210. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
TABLE 211. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
TABLE 212. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
TABLE 213. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
TABLE 214. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 215. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 216. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 217. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 218. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 219. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
TABLE 220. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
TABLE 221. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 222. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
TABLE 223. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 224. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 225. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 226. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 227. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 228. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
TABLE 229. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
TABLE 230. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
TABLE 231. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
TABLE 232. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
TABLE 233. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
TABLE 234. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 235. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 236. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 237. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 238. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 239. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
TABLE 240. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
TABLE 241. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 242. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
TABLE 243. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 244. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 245. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 246. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 247. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 248. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
TABLE 249. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
TABLE 250. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
TABLE 251. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
TABLE 252. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
TABLE 253. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
TABLE 254. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 255. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 256. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 257. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 258. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 259. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
TABLE 260. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
TABLE 261. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 262. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
TABLE 263. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 264. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 265. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 266. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 267. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 268. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
TABLE 269. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
TABLE 270. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
TABLE 271. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
TABLE 272. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
TABLE 273. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
TABLE 274. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 275. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 276. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 277. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 278. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 279. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
TABLE 280. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
TABLE 281. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 282. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
TABLE 283. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 284. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 285. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 286. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 287. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 288. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
TABLE 289. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
TABLE 290. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
TABLE 291. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
TABLE 292. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
TABLE 293. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
TABLE 294. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 295. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 296. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 297. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 298. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 299. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
TABLE 300. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
TABLE 301. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 302. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
TABLE 303. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 304. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 305. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 306. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 307. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 308. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
TABLE 309. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
TABLE 310. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
TABLE 311. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
TABLE 312. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
TABLE 313. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
TABLE 314. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 315. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 316. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 317. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 318. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 319. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
TABLE 320. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
TABLE 321. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 322. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
TABLE 323. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 324. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 325. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 326. GCC INFECTIOUS VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 327. GCC INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 328. GCC INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
TABLE 329. GCC INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
TABLE 330. GCC INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
TABLE 331. GCC INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
TABLE 332. GCC INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
TABLE 333. GCC INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
TABLE 334. GCC INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 335. GCC INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 336. GCC INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 337. GCC INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 338. GCC INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 339. GCC INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
TABLE 340. GCC INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
TABLE 341. GCC INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 342. GCC INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
TABLE 343. GCC INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 344. GCC INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 345. GCC INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 346. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 347. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 348. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
TABLE 349. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
TABLE 350. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
TABLE 351. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
TABLE 352. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
TABLE 353. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
TABLE 354. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 355. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 356. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 357. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 358. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 359. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
TABLE 360. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
TABLE 361. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 362. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
TABLE 363. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 364. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 365. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 366. BRICS INFECTIOUS VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 367. BRICS INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 368. BRICS INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
TABLE 369. BRICS INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
TABLE 370. BRICS INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
TABLE 371. BRICS INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
TABLE 372. BRICS INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
TABLE 373. BRICS INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
TABLE 374. BRICS INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 375. BRICS INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 376. BRICS INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 377. BRICS INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 378. BRICS INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 379. BRICS INFECTIOUS VAC

Companies Mentioned

The companies featured in this Infectious Vaccines market report include:
  • Adimmune Corporation
  • AstraZeneca plc
  • Bavarian Nordic
  • Bharat Biotech
  • Biological E Limited
  • BioNTech SE
  • CanSino Biologics
  • China National Biotechnology Group
  • CSL Limited
  • Dynavax Technologies
  • Emergent BioSolutions, Inc.
  • GlaxoSmithKline plc
  • Haffkine Bio-Pharmaceutical Corporation
  • Inovio Pharmaceuticals
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India
  • Sinovac Biotech Ltd.
  • Valneva SE
  • VBI Vaccines, Inc.

Table Information

Report AttributeDetails
No. of Pages187
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 38.23 Billion
Forecasted Market Value ( USD ) by 2032 $ 66.98 Billion
Compound Annual Growth Rate9.7%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Infectious Vaccine Collaboration and Licensing Deals 2016-2026 - Product Image

Infectious Vaccine Collaboration and Licensing Deals 2016-2026

  • Report
  • 300 Pages
  • Global
From
Vaccines Market by Type, Vaccine Combination, Disease Indication, Vaccine Classification, Route of Administration, Dosage, Age Group, End User - Global Forecast 2026-2032 - Product Image

Vaccines Market by Type, Vaccine Combination, Disease Indication, Vaccine Classification, Route of Administration, Dosage, Age Group, End User - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Nanomaterial-Based Adjuvants Vaccine Market - Global Forecast 2026-2032 - Product Image

Nanomaterial-Based Adjuvants Vaccine Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Vaccine Vials Market Outlook - Forecast Trends, Market Size, Share and Growth Analysis Report (2025-2034) - Product Image

Vaccine Vials Market Outlook - Forecast Trends, Market Size, Share and Growth Analysis Report (2025-2034)

  • Report
  • 350 Pages
  • Global
From
Latin America Vaccine Market Report and Forecast 2025-2034 - Product Image

Latin America Vaccine Market Report and Forecast 2025-2034

  • Report
  • 300 Pages
  • Latin America
From

About the Infectious Disease Vaccine Market

The Infectious Disease Vaccine market is a subset of the larger Infectious Diseases Drugs market. Vaccines are a form of preventive medicine, designed to protect individuals from contracting a particular infectious disease. Vaccines work by introducing a weakened or inactive form of the virus into the body, which stimulates the immune system to create antibodies that can fight off the virus if it is encountered in the future. Vaccines are typically administered through injection, but some are available in oral or nasal spray form. The Infectious Disease Vaccine market is highly competitive, with many companies developing and marketing vaccines for a variety of infectious diseases. Companies in the market include Merck, Pfizer, GlaxoSmithKline, Sanofi, Johnson & Johnson, and Novartis. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.